A LONG-TERM EXTENSION OF THE ARGX-117-2002 TRIAL TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY, EFFICACY, PHARMACODYNAMICS, PHARMACOKINETICS, AND IMMUNOGENICITY OF ARGX-117 IN ADULTS WITH MULTIFOCAL MOTOR NEUROPATHY (MMN)
- Registry ID
- ARGX-117-2003
- Source registry
- HEALTH_CANADA
- Status
- Closed
- Study type
- INTERVENTIONAL
- Sponsor
- ARGENX BV
- Start date
- 2025-02-06
- Completion date
- 2026-01-15
- Last update
- 2022-11-03
Conditions
- MULTIFOCAL MOTOR NEUROPATHY (MMN)
Related clinical trials
- A PHASE 3, RANDOMIZED, DOUBLE-BLINDED, DOUBLE-DUMMY STUDY EVALUATING THE
EFFICACY AND SAFETY OF EMPASIPRUBART VERSUS INTRAVENOUS IMMUNOGLOBULIN IN
ADULTS WITH MULTIFOCAL MOTOR NEUROPATHY
- A PHASE 2, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, STUDY TO EVALUATE
SAFETY, TOLERABILITY, PHARMACOMETRICS, AND EFFICACY OF DNTH103 IN ADULTS WITH
MULTIFOCAL MOTOR NEUROPATHY (MOMENTUM)
- A PHASE 2, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY, PHARMACOKINETICS, PHARMACODYNAMICS, AND IMMUNOGENICITY OF 2 DOSE REGIMENS OF ARGX-117 IN ADULTS WITH MULTIFOCAL MOTOR NEUROPATHY
View on source registry